
We Are Tecnovax
We are a biotechnology company with more than twenty years of experience in the development, production and global commercialization of new vaccines and immunotherapies to protect the life and productivity of animals. At Tecnovax we produce vaccines for livestock, aquatic animals and companion animals (dogs and cats) for a world that boasts more than 27 billion domestic and production animals that interact with a world on the move generating genetic recombination, resistance to antibiotics and new infectious variants. With more than one billion doses applied in five continents, we are key players in the global fight against the main infectious diseases that threaten life on the planet. We are Tecnovax. We do science that protects animals. |
Present in more than
24 countries
Leaders
in the national animal health vaccines market since
2014
7000 m2
of biopharmaceutical facilities
150
Collaborators
More than
1 billion
doses of vaccines administered.
We are Tecnovax.
We engage in scientific research that shields and safeguards animals.
- Tecnovax stands for vaccine technology.
- We specialize in isolating, identifying, and purifying infectious agents that affect animal health and developing vaccines from them.
- We are the leading company in the region in vaccines and immunotherapies that sells more doses annually in Argentina.
- Providean - (Products for animal life) is the brand name under which we market our vaccines.
- We develop tailor-made vaccines from field isolates.
- We develop vaccines for third parties as CMO (Contract Manufacturing Organization) for some of the leading global companies.




Tecnovax Foundation.


Tecnovax signs a long-term agreement with one of the main multinationals in the sector to produce biological products


Tecnovax launches its line of vaccines Providean Biologicos for livestock.


Tecnovax registers and launches its line of vaccines for livestock in Peru, Paraguay, Colombia, Bolivia and Uruguay.


Tecnovax launches its line of vaccines Providean Viratec for Family Animals and Providean Aquatec for salmon and trout in Chile.


Tecnovax registers and launches its Providean Viratec vaccine line in Colombia, Uruguay, Paraguay and Mexico.


First sales of Providean Aquatec vaccines to New Zealand.


Tecnovax registers and launches its line of vaccines Providean Biologicos and Providean Viratec in Brazil.


Tecnovax registers and launches its line of vaccines Providean Biologicos and Providean Viratec in the Middle East.


First sales of Providean Hidatec vaccines to Italy under a special import permit.


Opening of new offices and R&D laboratory
Our Legacy
Our story begins long before the first vaccine we developed.
It begins with the CEVAN (Centro de Virología Animal – Animal Virology Center part of CONICET), which was founded in the 70’s with the support of Dr. Bernardo Houssay – Nobel Prize in Medicine – then president of CONICET, with the intention of developing vaccines and diagnostic technologies to control a disease that was ravaging Argentina: Foot and Mouth Disease.
Tecnovax emerged as the natural evolution of the joint efforts of scientists who were part of that institution. Nowadays, within the private sector and backed by a group of three young entrepreneurs, the company translates scientific advances into new vaccines to attend to the needs of the new millennium.




Dr. José La Torre
Virólogo fundador del CEVAN – Centro de Virología Animal – CONICET
Origen e inspiración de Tecnovax
Thus, in 2003, Tecnovax was born, founded by Diego La Torre. Matías and Nicolás Grosman joined the initial project as co-founders and the three of them, together with a huge team of collaborators, have led the company to its present at the forefront of technology.
Two decades after its birth, Tecnovax is present in five continents and has administered more than one billion doses to protect animal health, thus consolidating its position as a global leader in the fight against infectious diseases and pandemic outbreaks that threaten life on the planet.
Our history
Tecnovax is a biotechnology company that specializes in vaccines and immunotherapies for animal health.
It was founded in 2003, and it specializes in the manufacture of biological products for one of the main multinationals in the sector after the emergence of “Bovine Spongiform Encephalopathy” (Mad Cow disease) and later launched its own brand in the market.
In 2004, the construction of a modern 2000 m2 plant located in the City of Buenos Aires is completed. The plant is GMP certified and qualifies as BSL-3 (biosafety level 3). Tecnovax enters into a long-term agreement with one of the main multinational companies in the industry to manufacture biologics.
In 2006, Tecnovax was invited to CanaryTech, a forum of high-tech companies in Spain, and was recognized for its rapid growth in the biotechnology industry in Latin America. The export campaign to Africa and the Middle East was also launched from CanaryTech.
This launch coincided with the completion of a new area for lyophilization and automatic packaging of injectable products.
In the same year and after an arduous auditing process, the company began exporting to more than 15 countries.
In 2007, Tecnovax decided to launch its own line of vaccines in the local market under the brand name Providean. The launching coincided with an important rabies outbreak in the north of Argentina, which allowed the laboratory to become the main source of vaccines to contain the disease.
The success achieved by the company resulted in a significant growth in the vaccines produced: 57,202,218 doses up to 2008. With this result and the objective of meeting the growing demand, the construction of a new plant of 2000 m2 located in the city of Mercedes, Province of Buenos Aires was promoted.
Since 2014, Tecnovax is the No. 1 company in doses commercialized in the domestic animal health vaccines market. In 2017, the 2400m2 Logistics Distribution Center and its administrative offices were inaugurated in Victoria, Province of Buenos Aires. In addition, the constant search for new technologies led the company to enter, in recent years, into several research and development agreements with the Argentine National Secretariat of Science and Technology, CONICET’s Animal Virology Center and the companies Ag-Research and DNA Investments -both from of New Zealand- for the development of vaccines using recombinant DNA technology. To achieve a more agile and efficient commercialization of the products at international level, Tecnovax has subsidiaries in Chile (Tecnovax Chile S.A.), Brazil (Tecnovax do Brasil Importacao e Comercio de Productos Veterinarios LTDA) and Uruguay (Tecnovax Uruguay S.A.). Currently, Tecnovax exports its three product lines for ruminants, companion animals and aquatic animals to 24 countries. It is the leading company in vaccines administered in the region and has 150 employees. |
Our Purpose
To protect and extend the life of companion and production animals and their permanent link to humankind.
To contribute to universal welfare and progress, consolidate sanitary safety and promote the production of quality animal feed on a large scale.
To translate research and science into more potent organisms and immune systems to fight infectious and critical animal diseases.
To protect animals and people around the world.
To make a valuable contribution to veterinary science.
To focus on passion for science, research, and operational excellence.
To contribute to the development of each of the countries in which we operate.
Tecnovax uses state-of-the-art technology to develop highly effective vaccines and immunotherapies that protect and prolong the life of family and production animals and their permanent link to mankind.
Through immunization obtained through innovative products and services, Tecnovax contributes to international welfare and progress, consolidates sanitary safety and boosts the production of quality animal feed on a large scale.
Tecnovax translates research and science into more powerful organisms and immune systems to fight infectious and critical animal diseases. Through a valuable contribution to veterinary science and relying on the best technology, Tecnovax protects animals and people around the world.
Focusing on the passion for science, research and operational excellence, Tecnovax also contributes to the development of each of the countries in which it operates, through the creation of qualified work, and its collaboration on the training of expert talent for the development and commercialization of products with high technological value.
Certifications












Our Facilities


Luis Viale Production Facility
Modern plant of 2000 m2, built in 2004. Located in the City of Buenos Aires, it was designed under the strict guidelines of the GMP standard and qualifies as biosafety level 3 (BSL-3) to protect the personnel, the product, and the environment. In addition, the plant is GMP certified.


Mercedes Production Facility
2,800 m2 plant located in the city of Mercedes, Province of Buenos Aires. It houses a BSL-3 vivarium for testing aquaculture vaccines. This plant tests all batches of product destined for the Chilean salmonid vaccine market.


Offices, distribution center and R&D laboratory
Our commercial offices, distribution center and, soon, an innovative research and development laboratory are located in Parque Uruguay, San Fernando, Province of Buenos Aires. The R&D lab will qualify as BSL-3, protecting the personnel, the product and the environment.



